Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
04:30pm, Thursday, 26'th Oct 2023
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
11:18am, Tuesday, 24'th Oct 2023
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
04:30pm, Tuesday, 30'th May 2023
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
07:30am, Friday, 03'rd Feb 2023
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the comp
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
11:18am, Wednesday, 25'th Jan 2023
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Dow Surges 150 Points; Crude Oil Falls Sharply
07:34pm, Monday, 14'th Nov 2022 Benzinga
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.
The Dow traded up 0.45% to 33,898.95 while the NASDAQ rose 0.11% to 11,335.52. The S
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
08:30pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
04:30pm, Monday, 31'st Oct 2022
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company wi
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
08:30pm, Thursday, 20'th Oct 2022 GlobeNewswire Inc.
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
04:30pm, Thursday, 20'th Oct 2022
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –
Albertsons Companies, Domino's Pizza And Other Big Gainers From Thursday
06:46am, Friday, 14'th Oct 2022 Benzinga
U.S. stocks closed higher on Thursday, with the Dow Jones jumping over 800 points. Here is the list of some big stocks recording gains in the previous session.
Nutex Health Inc. (NASDAQ: NUTX) jumped
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
02:05pm, Thursday, 13'th Oct 2022 Benzinga
Upgrades
TD Securities upgraded the previous rating for BCE Inc (NYSE:BCE) from Hold to Buy. In the second quarter, BCE showed an EPS of $0.68, compared to $0.68 from the year-ago quarter. The current
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022
02:12pm, Monday, 15'th Aug 2022 Benzinga
Upgrades
Kalinowski Research upgraded the previous rating for McDonald's Corp (NYSE:MCD) from Neutral to Buy. For the second quarter, McDonald's had an EPS of $2.55, compared to year-ago quarter EPS
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
09:55am, Friday, 29'th Jul 2022 Benzinga
Gainers
Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 20
